24 results about "Kidney inflammation" patented technology

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

The invention relates to a human recombinant GDF15 protein and application thereof in preparation of drugs for preventing and treating sepsis acute kidney injury, and belongs to the technical field of biological medicines. In order to solve the problem that an effective prevention and treatment scheme for improving SA-AKI by inhibiting oxygen death is lacked in existing clinical and research, the invention provides a human recombinant GDF15 protein of which the coding gene nucleotide sequence is shown as SEQ ID No: 1. Animal experiment results show that by intraperitoneal injection of the human recombinant GDF15 protein, kidney inflammation of sepsis mice can be relieved, and expression of PGAM5 can be down-regulated. Cell experiment results show that when the human recombinant GDF15 protein is given, LPS-induced USF2 increase can be inhibited. The human recombinant GDF15 protein provided by the invention can improve SA-AKI by inhibiting oxygen death and inflammation, provides a new idea and an intervention target for prevention and treatment of SA-AKI, and shows a good clinical application prospect.

The invention discloses a preparation method and application of hydrolyzed casein peptide capable of reducing uric acid and facilitating gout attack prevention and gout symptom improvement, belongs to the technical field of biology, and has a wide application prospect. The casein hydrolysate peptide prepared by the method disclosed by the invention can effectively reduce uric acid, and is beneficial to preventing gout attack and improving gout symptoms by the following ways: 1, inhibiting the activity of xanthine oxidase (UA enzyme), and reducing the generation of uric acid; 2, metal ions such as Ca < 2 + > and Na < + > are complexed to prevent generation of urate crystals, so that gout attack can be prevented; 3, the microenvironment of an articular cavity is improved, urate crystals are dissolved, and the gout symptom can be improved; and 4, liver and kidney inflammation caused by high uric acid is relieved.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention discloses raspberry leaf polysaccharide as well as a preparation method and application thereof. The average relative molecular weight of the raspberry leaf polysaccharide is 44755 Da, and the raspberry leaf polysaccharide is mainly prepared from mannose, glucose, rhamnose, glucosamine, galactosamine, glucuronic acid, galactose, xylose and arabinose according to the molar ratio of (3.138): (0.894): (12.349): (4.590): (26.498): (18.681): (22.842): (2.690): (8.317). Besides, methylation and nuclear magnetic resonance analysis show that the raspberry leaf polysaccharide is complex polysaccharide, and it can be reasonably deduced that the raspberry leaf polysaccharide is mainly composed of a large number of HG structural domain-like structures and a part of RG-I structures with side chains. Meanwhile, the raspberry leaf polysaccharide disclosed by the invention can be used for inhibiting the injury of kidney tissues and reducing the generation of kidney inflammatory factors.

The invention discloses an ICAM-1 targeting engineered exosome-metal phenol nano-drug as well as a preparation method and application thereof. The nano-drug is composed of an engineered exosome and metal phenol nano-particles, wherein ICAM-1 targeting VHH antibodies are displayed on the surface of the engineered exosome, and the metal phenol nano-particles are encapsulated in the engineered exosome and formed by self-assembly of iron ions and resveratrol. The MPNs are efficiently loaded into the exosome through an electroporation method, and a composite nano delivery system (ICAM (at) Exo (at) MPNs) is constructed. The system has multiple advantages of active targeting of kidney inflammation parts, active oxygen responsive drug release, simulation of antioxidant enzyme activity, regulation and control of macrophage functions and the like. The ICAM (at) Exo (at) MPNs can remarkably relieve kidney crystal deposition, oxidative stress and inflammatory response induced by calcium oxalate, and the protective effect of the ICAM (at) Exo (at) MPNs is related to regulation and control of an SLC1A7 / MerTK signal channel. The invention provides an efficient and safe new strategy for preventing and treating the calcium oxalate kidney injury.

The invention relates to the technical field of medicines, in particular to application of ginsenoside in preparation of medicines for improving kidney inflammation and enhancing uric acid excretion. It is found for the first time that ginsenoside Rg2 can reduce systematic and kidney inflammatory reactions by reducing expression levels of inflammatory factors LPS, TNF-alpha and IL-1beta; by down-regulating the expression level of fibrosis marker molecules alpha-SMA and Smad3, the effect of improving HUA-related kidney inflammation and fibrosis is achieved; by up-regulating the expression levels of uric acid transporters OAT1, OAT3 and ABCG2, the active transport and excretion ability of the kidney to uric acid is enhanced. The discovery can generate great influence on research and treatment of relieving hyperuricemia, and has clinical practical value.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

Provided is use of a complement factor B inhibitor in the preparation of a drug for treating or preventing IgA nephropathy or a disease or condition related thereto. Specifically, provided is use of a compound represented by formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof in the preparation of a drug for treating or preventing IgA nephropathy or a disease or condition related thereto. The drug can effectively reduce creatinine and urea nitrogen levels in patients with IgA nephropathy, reduce renal inflammation and / or fibrosis in patients with IgA nephropathy, and provide a novel, effective and safe option for the treatment of IgA nephropathy.

The invention features methods for the treatment of Alport syndrome using a polypeptide containing an extracellular ActRII variant, such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant. The polypeptide may include an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer. Treatment of Alport syndrome with a polypeptide described herein may reduce kidney inflammation, reduce kidney fibrosis, slow disease progression, and / or improve kidney function, which may reduce or delay the need for a kidney transplant or dialysis.

The present invention relates to a bacterial agent for alleviating hyperuricemia and its application. The bacterial strain in the bacterial agent for alleviating hyperuricemia is Akkermansia muciniphila. Akkermansia muciniphila Akk09 strain and Bifidobacterium animalis subsp. lactis Bifidobacterium animalum subsp. milk The two strains are composed of the BLa80 strain. They complement and enhance each other, synergizing their effects in alleviating hyperuricemia, specifically by lowering blood uric acid levels; inhibiting xanthine oxidase activity; reducing urea nitrogen and creatinine levels; alleviating kidney inflammation and oxidative stress caused by hyperuricemia; and regulating intestinal flora disturbances caused by hyperuricemia.

The invention provides application of a composition beneficial to pet kidney health, the composition comprises a yeast extract I, Omega-3 fatty acid, a turmeric extract, a yeast extract II, a green tea extract, a gynostemma pentaphylla extract and glutamine, and the composition is applied to protection of pet kidney health. The yeast extract I contains SAM-e, the turmeric extract contains curcumin, and the yeast extract II contains glutathione. The traditional Chinese medicine composition disclosed by the invention shows a curative effect obviously superior to that of a traditional product such as Shenan capsules in the aspects of reducing renal function indexes, improving pathological changes of kidney tissues, inhibiting expression of related genes of kidney inflammation and the like. Experimental results show that the optimal effects are achieved in five dimensions of oxidative stress, inflammatory response, fat metabolism, safety and mechanism verification, and the effectiveness and safety of the composition are fully proved.

The invention relates to a bacterial agent for relieving hyperuricemia and an application of the bacterial agent. The bacterial strain in the bacterial agent for relieving the hyperuricemia is composed of an Ackermania muciniphila Akk09 bacterial strain and a Bifidobacterium animalis subsp. Lactis BLa80 bacterial strain, and the bacterial strain in the bacterial agent for relieving the hyperuricemia is composed of an Akkermania muciniphila Akk09 bacterial strain and a Bifidobacterium animalis subsp. Lactis BLa80 bacterial strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect on the aspect of relieving hyperuricemia, specifically, the level of blood uric acid is reduced; the activity of xanthine oxidase is inhibited; the urea nitrogen and creatinine levels are reduced; kidney inflammation and oxidative stress caused by hyperuricemia are relieved; the intestinal flora disorder caused by high uric acid is regulated.

The invention provides an application of dihydroberberine in preparation of a medicine for treating diabetic nephropathy. The application finds that dihydroberberine can obviously relieve kidney inflammation and fibrosis lesion in diabetic nephropathy and has an obvious protection effect on renal tubular epithelial cell injury induced by high glucose and high fat, and the bioavailability is obviously improved compared with berberine.

The invention provides application of pigeon pea extract and active ingredients in preparation of drugs or functional food for relieving hyperuricemia. Animal experiment research finds that intervention of pigeon pea extract and pinostrobin significantly reduces serum uric acid content of a hyperuricemia mouse, prevents serum creatinine and / or serum urea nitrogen in vivo from increasing, and can increase urine urea nitrogen and / or urine creatinine excretion; meanwhile, the pigeonpea extract and the pinostrobin can restore the kidney and liver coefficients of a hyperuricemia mouse to a normal level, remarkably relieve kidney injury caused by hyperuricemia, inhibit kidney inflammation / fibrosis reaction and restore the physiological state of the kidney to the level of a normal mouse.

The present disclosure belongs to the technical field of biological medicine, and particularly relates to the application of finerenone in the preparation of a drug for treating hypertensive renal injury. The present disclosure provides the application of finerenone in the preparation of a drug for preventing and / or treating hypertensive renal injury, specifically, by using a deoxycorticosterone acetate-salt-induced hypertensive mouse model and a primary mouse renal tubular epithelial cell-bone marrow-derived macrophage co-culture model, it is first revealed that aldosterone and salt corticosteroid receptor signals mediate cell-to-cell communication by promoting PANX1-dependent ATP release in renal tubular epithelial cells, and then activate macrophage P2X7, activate NLRP3-mediated macrophage pyroptosis, and aggravate the molecular mechanism of aldosterone-driven renal inflammation and fibrosis. The present disclosure also provides the application of a substance targeting a PANX1 / extracellular ATP / P2X7 signal axis in the preparation of a drug for preventing and / or treating hypertensive renal injury.

The application belongs to the technical field of plant lactobacillus, and particularly relates to a plant lactobacillus LPU3 and application of the plant lactobacillus LPU3 in relieving hyperuricemia. The plant lactobacillus LPU3 has the functions of degrading uric acid in vitro, inhibiting xanthine oxidase in vitro, intervening hyperuricemia, inhibiting metabolic enzymes, improving kidney injury caused by hyperuricemia, improving kidney inflammation and oxidative stress caused by hyperuricemia, and improving intestinal flora disorder caused by hyperuricemia.

The invention discloses a compound and application thereof in preparation of a medicine for treating systemic lupus erythematosus. A series of novel small molecule compounds are designed based on DHA by utilizing a PROTAC technology, the novel small molecule compounds have ligands combined with E3 ubiquitin ligase protein and ligands for targeted degradation of protein, the compound shown in the formula (II-1) degrades CARD6 protein through an ubiquitin enzyme system, phenotypic polarization of THP-1 macrophages induced by LPS + IFN-gamma to M1 can be inhibited, CARD6 can be degraded, and the compound can be used for preparing a medicine for preventing and controlling the expression of the compound in the formula (II-1). The inflammation is improved; the compound can effectively improve the renal function of an MRL / lpr model mouse and relieve the renal inflammatory response of the MRL / lpr mouse, can be further developed into a medicine for treating SLE, and has a wide application prospect.

The present invention provides a composition having the effects of lowering uric acid and improving renal function, and its preparation method, application and product, which belong to the field of application of traditional Chinese medicine. The composition is composed of the following components: raw astragalus, smilax glabra, mistletoe, salvia miltiorrhiza and orientalis. The composition provided by the present invention is used in combination with raw astragalus, smilax glabra, mistletoe, salvia miltiorrhiza and orientalis, and the obtained composition can be used to treat hyperuricemia or its related diseases, with significant efficacy and small toxic and side effects. The composition is used for the late treatment of hyperuricemia, treatment of joint pain, and poor flexion and extension. At the same time, the composition has a certain kidney protection effect, which can reduce renal inflammation and fibrosis.

The present invention relates to the field of biomedical technologies, and particularly relates to a drug composition for reducing uric acid, a preparation method thereof, and an application thereof. The drug composition, calculated by weight parts, mainly comprises the following raw materials: 35-45 parts of Poria cocos, 20-25 parts of Alisma orientale, 20-25 parts of Atractylodes lancea, and 20-25 parts of Pueraria lobata. Using this drug composition can reduce the uric acid content in the serum of hyperuricemia mice, increase the uric acid excretion amount of hyperuricemia mice, improve the renal function of hyperuricemia mice, and inhibit kidney inflammation.

The invention relates to application of rosaxostat in preparation of a medicine for relieving the CKD kidney inflammation level. The application finds that 1, the plasma SDF-1 level of a CKD patient taking the rosaxostat is remarkably increased, and the proportion of peripheral blood anti-inflammatory myeloid suppressor cells is remarkably increased; 2, a mouse renal fibrosis model research finds that the proportion of anti-inflammatory myelosuppression cells in the spleen, peripheral blood and kidney of a mouse is increased after the mouse takes the rosaxostat; the expression of HIF-1alpha in the spleen and the kidney is increased, but the expression of SDF-1 in the spleen is increased, and the expression of SDF-1 in the kidney is not obviously changed. It is shown that the Rosaxostat relieves the CKD kidney inflammation level by regulating and controlling the spleen-derived myeloid inhibition cell typing.

The invention relates to an application of a compound 2-(2-(5-methyl-2-oxotetrahydrofuran-3-yl) acetyl) hydrazine-1-thioformamide in preparation of a medicine for treating acute kidney injury, in particular to an application of the compound 2-(2-(5-methyl-2-oxotetrahydrofuran-3-yl) acetyl) hydrazine-1-thioformamide. The compound provided by the invention can effectively reduce cell injury and inflammatory response, and reduce expression and secretion levels of cell inflammatory factors; the traditional Chinese medicine composition can effectively improve the pathological level of kidney tissues of acute kidney injury animals in vivo, inhibit protein expression of a kidney injury factor KIM-1, reduce the levels of creatinine and urea nitrogen in serum of AKI mice and inhibit recruitment of inflammatory cells such as macrophages and neutrophils, so that kidney inflammations are relieved, and the traditional Chinese medicine composition has excellent prevention and treatment effects on acute kidney injury and inflammations.

Positron emission tomography (PET) is a bioimaging technique that relies on positron emitting probes. PET probes can be obtained from a non-labeled probe by a late-stage radiolabelling step with a radionuclide, prior to the injection of the probe to the patient. Because of the short half-life duration of most radionuclides, the radiolabelling step must be rapid. The present invention provides a method allowing the rapid embedding of 68Ga into particles comprising polydopamine. The particles labeled with the method are very stable and are obtained in high yield with a high purity. It has been shown that radiolabeled particles obtained with the method of the invention and functionalized with antibodies were efficient in revealing lung and kidney inflammation via a whole-body PET scan in a LPS-induced sepsis mouse model. Such probes, when they further incorporate magnetic nanoparticles, carry a high potential to improve the diagnosis of inflammation via PET-MRI.